These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 32770459)
1. Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches. Luo X; Zhao Y; Tang P; Du X; Li F; Wang Q; Li R; He J Mol Divers; 2021 Feb; 25(1):367-382. PubMed ID: 32770459 [TBL] [Abstract][Full Text] [Related]
2. Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6. Yousuf M; Shamsi A; Khan P; Shahbaaz M; AlAjmi MF; Hussain A; Hassan GM; Islam A; Rizwanul Haque QM; Hassan MI Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429317 [TBL] [Abstract][Full Text] [Related]
3. Reduced state transition barrier of CDK6 from open to closed state induced by Thr177 phosphorylation and its implication in binding modes of inhibitors. He H; Xu J; Xie W; Guo QL; Jiang FL; Liu Y Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):501-512. PubMed ID: 29108955 [TBL] [Abstract][Full Text] [Related]
4. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations. Susanti NMP; Damayanti S; Kartasasmita RE; Tjahjono DH Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948218 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening. Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188 [No Abstract] [Full Text] [Related]
6. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex. Khuntawee W; Rungrotmongkol T; Hannongbua S J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011 [TBL] [Abstract][Full Text] [Related]
7. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675 [TBL] [Abstract][Full Text] [Related]
8. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6. Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753 [TBL] [Abstract][Full Text] [Related]
9. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening. Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757 [TBL] [Abstract][Full Text] [Related]
10. Discovery and SARs of 5-Chloro- Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations. Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817 [TBL] [Abstract][Full Text] [Related]
12. Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies. Yousuf M; Shamsi A; Queen A; Shahbaaz M; Khan P; Hussain A; Alajmi MF; Rizwanul Haque QM; Imtaiyaz Hassan M J Cell Biochem; 2021 Aug; 122(8):897-910. PubMed ID: 33829554 [TBL] [Abstract][Full Text] [Related]
13. Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6. Basati G; Saffari-Chaleshtori J; Abbaszadeh S; Asadi-Samani M; Ashrafi-Dehkordi K Curr Drug Res Rev; 2019; 11(2):135-141. PubMed ID: 31875784 [TBL] [Abstract][Full Text] [Related]
14. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. Nandha Premnath P; Craig S; McInnes C J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946 [TBL] [Abstract][Full Text] [Related]
15. Virtual Screening Using Pharmacophore Models Retrieved from Molecular Dynamic Simulations. Polishchuk P; Kutlushina A; Bashirova D; Mokshyna O; Madzhidov T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757043 [TBL] [Abstract][Full Text] [Related]
16. Unveiling Conformational States of CDK6 Caused by Binding of Vcyclin Protein and Inhibitor by Combining Gaussian Accelerated Molecular Dynamics and Deep Learning. Zhao L; Wang J; Yang W; Zhao K; Sun Q; Chen J Molecules; 2024 Jun; 29(11):. PubMed ID: 38893554 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model. Liang JW; Wang MY; Wang S; Li SL; Li WQ; Meng FH J Enzyme Inhib Med Chem; 2020 Dec; 35(1):235-244. PubMed ID: 31760818 [TBL] [Abstract][Full Text] [Related]
18. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability. Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527 [TBL] [Abstract][Full Text] [Related]
19. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy. Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444 [TBL] [Abstract][Full Text] [Related]
20. The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study. Susanti NMP; Kurniawan F; Damayanti S; Kartasasmita RE; Tjahjono DH Sci Rep; 2024 Oct; 14(1):23505. PubMed ID: 39379427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]